about
Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeuticsNew pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugsTherapeutic targets of brain insulin resistance in sporadic Alzheimer's diseaseProfile of gantenerumab and its potential in the treatment of Alzheimer's diseaseBrain insulin resistance and deficiency as therapeutic targets in Alzheimer's diseaseBapineuzumab alters aβ composition: implications for the amyloid cascade hypothesis and anti-amyloid immunotherapyFLZ alleviates the memory deficits in transgenic mouse model of Alzheimer's disease via decreasing beta-amyloid production and tau hyperphosphorylationWhite matter changes in dementia: role of impaired drainage of interstitial fluid.Innovating aging: promises and pitfalls on the road to life extension.The biochemical aftermath of anti-amyloid immunotherapy.Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificityImmunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse modelAbhorring the vacuum: use of Alzheimer’s disease medications in frontotemporal dementia.First administration of the Fc-attenuated anti-β amyloid antibody GSK933776 to patients with mild Alzheimer's disease: a randomized, placebo-controlled studyAmyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis.Advances in recent patent and clinical trial drug development for Alzheimer's disease.Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's diseaseDevelopment of Immunoassays for the Quantitative Assessment of Amyloid-β in the Presence of Therapeutic Antibody: Application to Pre-Clinical Studies.Automated Hippocampal Subfield Segmentation at 7T MRI.Natural products as a source of Alzheimer's drug leads.Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathologyIs Alzheimer's disease amyloidosis the result of a repair mechanism gone astray?Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer's disease.Therapeutic potential of vaccines for Alzheimer's disease.Therapeutic applications of antibodies in non-infectious neurodegenerative diseasesSolanezumab for Alzheimer's disease.Immunotherapy for tauopathies.Pharmacologists and Alzheimer disease therapy: to boldly go where no scientist has gone before.Solanezumab for the treatment of mild-to-moderate Alzheimer's disease.Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.Gantenerumab for the treatment of Alzheimer's disease.What's hAPPening at synapses? The role of amyloid β-protein precursor and β-amyloid in neurological disorders.Novel disease-modifying therapeutics for the treatment of Alzheimer's disease.Immunogenicity of DNA- and recombinant protein-based Alzheimer disease epitope vaccines.Antibody-Based Drugs and Approaches Against Amyloid-β Species for Alzheimer's Disease Immunotherapy.Recent advances in the development of immunotherapies for tauopathiesAmyloid β oligomers (AβOs) in Alzheimer's disease.Failure of perivascular drainage of β-amyloid in cerebral amyloid angiopathy.Amyloid imaging for Alzheimer's disease.Monoclonal antibodies against β-amyloid (Aβ) for the treatment of Alzheimer's disease: the Aβ target at a crossroads.
P2860
Q26822002-09BD9B98-D562-4267-8B8B-C5E224EF7201Q26866006-053EAB14-ADB2-4FD6-8134-68903B9AF6A3Q27021700-C31D80FC-8394-4D9A-B8FA-EBEA8E1EC68AQ27027675-936682B1-3093-4C40-A447-99F49B67952BQ28259585-78C6F4C5-D06B-4C8F-AC28-93B15BEF02FEQ28488690-D232F1D0-F4E5-40BA-B810-1ACFBD838016Q28534810-88193A54-59CC-4B34-B95A-01966207D14CQ30880445-AAD30D81-1A5B-4915-897F-4AC2C3210C97Q33954643-5F0BAEE2-A3CE-4174-A594-064A1E4178FDQ34221510-3E22F679-7CFE-4231-AA31-F8B8959B5AE9Q34701388-2325C6FD-964D-4AA0-BF99-64289E69D7C4Q35104249-22504DB5-73A6-42C9-8805-1B13344F13BFQ35107027-0E528DE7-51C9-4EDB-BEDD-0B414450EC02Q35195612-1461C09D-C6CC-415B-BCCA-A6306C822849Q35327172-5675C024-4F0A-4BF6-B722-6D04E92B1A17Q35738142-031828F8-0754-4C37-B2AD-CD27A5CECF99Q35997824-690BE89C-1FB0-4FD6-B7FF-9EAF2C18B69AQ36930444-CD6A8B8B-05AC-4D21-863A-EB5537FA6223Q37004118-FFA79252-2963-4C4C-A8A6-F7B49441B1ADQ37029561-3A49C46A-20B0-49D9-9BF8-FC9171101CFCQ37311364-24A20E73-34A3-4B5F-8BE8-67842DE62290Q37698598-BAA9884C-1BA7-4831-9C7E-36A0976442E4Q37810956-A92A2DAF-4A8D-4713-A13F-1E1BE099BD17Q37842339-BBE66D59-6F7E-487A-998F-59085F844A73Q37862785-EA1BB42B-03F2-4278-B50E-77FF630A695DQ37866811-E13BF878-CE7C-4A92-A968-712B009821AAQ37899064-0051970D-A1ED-45F6-BE0B-D6A1D6DD4933Q37910243-C7150613-B5FC-4B49-AEC4-54B472A28E2CQ37979840-408DD40F-EB1B-4A9B-A63B-4D6AE7E700BDQ37984574-F93D2124-2977-4FBE-961F-F9B01B8F9773Q38009878-EDAB5652-2F64-4067-8EC2-B90DA9AC6D27Q38038399-630D617E-B08D-4673-9712-6B5076D7DD8AQ38127470-6A806601-E5E8-4927-8495-19CF0E7F0672Q38187861-2A0E258C-79AC-4A7E-A821-D484FC81B7ACQ38807908-640FE8DA-B4D1-4850-A032-F53FE273CEF8Q42778736-BD7E0DF3-F3E6-4422-8F26-9C4319AE65D0Q47339779-8CC9040A-EDF3-4502-8C48-96EBF6A6957BQ48707455-80C0392E-870A-4DF7-9544-1C72C7D76066Q48811049-8CB030B2-9FCC-493D-94A7-4EFFC6330B92Q53318372-FE0DA794-8B99-47FB-BB76-72A55148542B
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Bapineuzumab
@ast
Bapineuzumab
@en
Bapineuzumab
@nl
type
label
Bapineuzumab
@ast
Bapineuzumab
@en
Bapineuzumab
@nl
prefLabel
Bapineuzumab
@ast
Bapineuzumab
@en
Bapineuzumab
@nl
P2860
P1476
Bapineuzumab
@en
P2093
Geoffrey A Kerchner
P2860
P304
P356
10.1517/14712598.2010.493872
P407
P50
P577
2010-07-01T00:00:00Z